Publicacións en colaboración con investigadores/as de Hospital Morales Meseguer (112)

2024

  1. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study

    The Lancet Haematology, Vol. 11, Núm. 8, pp. e606-e616

2023

  1. Congenital factor XI deficiency and risk of heart failure in humans

    Journal of Thrombosis and Haemostasis

  2. Impact of genetic structural variants in factor XI deficiency: identification, accurate characterization, and inferred mechanism by long-read sequencing

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 7, pp. 1779-1788

  3. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  4. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin

    Biomedicine and Pharmacotherapy, Vol. 168

  5. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

    Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323

  6. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells

    Frontiers in Molecular Biosciences, Vol. 10

2022

  1. Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients

    Cancers, Vol. 14, Núm. 13

  2. Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer

    Cancers, Vol. 14, Núm. 10

2021

  1. A pilot study on the impact of congenital thrombophilia in COVID-19

    European Journal of Clinical Investigation

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia

    Medicina Clinica, Vol. 157, Núm. 4, pp. 191-198

  4. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma

    Journal of Thrombosis and Thrombolysis, Vol. 52, Núm. 3, pp. 848-853

  5. Minimal residual disease in multiple myeloma: Something old, something new

    Cancers, Vol. 13, Núm. 17

  6. Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach

    OncoImmunology, Vol. 9, Núm. 1

  2. Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation

    Mayo Clinic Proceedings, Vol. 95, Núm. 11, pp. 2360-2369

  3. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: The Murcia AF project

    Thrombosis and Haemostasis, Vol. 120, Núm. 8, pp. 1200-1207

  4. Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2400-2407

2019

  1. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy

    Cellular Oncology, Vol. 42, Núm. 5, pp. 627-644